Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test
Read More Healthcare Industry News Why MedImpact’s brand overhaul matters as U.S. payers demand lower drug costs and more control MedImpact unveils a refreshed identity to emphasize modular healthcare solutions, digital innovation, and payer empowerment—read the full analysis now. byPallavi MadhirajuSeptember 14, 2025